Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 3/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.34 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22930120 | 0.97 | KDM4E (0.44) | KDM4ECYP1A2CYP2D6CYP2C19POLB | |
| SCHEMBL22837632 | 0.97 | KDM4E (0.44) | KDM4ECYP1A2CYP2D6CYP2C19POLB | |
| SCHEMBL10914222 | 0.97 | KDM4E (0.44) | KDM4ECYP1A2CYP2D6CYP2C19POLB | |
| SCHEMBL18908652 | 0.97 | KDM4E (0.44) | KDM4ECYP1A2CYP2D6CYP2C19POLB | |
| SCHEMBL18908756 | 0.97 | KDM4E (0.44) | KDM4ECYP1A2CYP2D6CYP2C19POLB | |
| SCHEMBL18908660 | 0.97 | KDM4E (0.44) | KDM4ECYP1A2CYP2D6CYP2C19POLB | |
| SCHEMBL20562604 | 0.92 | KDM4E (0.39) | KDM4ECYP1A2CYP2D6CYP2C19POLB | |
| SCHEMBL12380197 | 0.89 | HSD17B10 (0.41) | KDM4ECYP1A2CYP2D6CYP2C19POLB | |
| SCHEMBL20562681 | 0.89 | KDM4E (0.41) | KDM4ECYP1A2CYP2D6CYP2C19POLB | |
| SCHEMBL20562213 | 0.89 | KDM4E (0.41) | KDM4ECYP1A2CYP2D6CYP2C19POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3356014-A1 | ABSORPTION AGENT AND A METHOD FOR SELECTIVELY REMOVING HYDROGEN SULPHIDE | BASF SE (DE) | 2018-08-08 | — | — | EP | claimed |
| CN-108025248-A | Absorbent and process for selective removal of hydrogen sulfide | 巴斯夫欧洲公司 | 2018-05-11 | — | — | CN | claimed |
| US-20220017432-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | Reiley Pharmaceuticals, Inc. | 2022-01-20 | — | — | US | disclosed |
| CN-108367232-B | Acid gas enrichment method and system | 巴斯夫欧洲公司 | 2021-06-01 | — | — | CN | disclosed |
| US-10913752-B2 | Bivalent bromodomain inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-10875769-B2 | Acid gas enrichment method and system | BASF SE (DE) | 2020-12-29 | — | — | US | disclosed |
| US-20200255291-A1 | ACID GAS ENRICHMENT METHOD AND SYSTEM | BASF SE (DE) | 2020-08-13 | — | — | US | disclosed |
| US-20200172553-A9 | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-04 | — | — | US | disclosed |
| EP-3386608-B1 | METHOD AND INSTALLATION FOR ACID GAS ENRICHMENT | BASF SE (DE) | 2020-03-18 | — | — | EP | disclosed |
| US-20190169084-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | Reiley Pharmaceuticals, Inc. | 2019-06-06 | — | — | US | disclosed |
| EP-3386608-A1 | ACID GAS ENRICHMENT METHOD AND SYSTEM | BASF SE (DE) | 2018-10-17 | — | — | EP | disclosed |
| US-8034898-B2 | Methods of collagen imaging | Collagen Medical, LLC (US) | 2011-10-11 | — | — | US | disclosed |
| US-20100221261-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2010-09-02 | — | — | US | disclosed |
| US-7645741-B2 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; bioavailability; coupling; chemical intermediates | AEGERA THERAPEUTICS, INC. | 2010-01-12 | — | — | US | disclosed |
| US-7579320-B2 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. | 2009-08-25 | — | — | US | disclosed |
| US-20080207525-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; bioavailability; coupling; chemical intermediates | PHARMASCIENCE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080069812-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents | AEGERA THERAPEUTICS, INC. (CA) | 2008-03-20 | — | — | US | disclosed |
| US-20080058636-A1 | METHODS OF MYOCARDIAL IMAGING | EPIX PHARMACEUTICALS, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080044360-A1 | METHODS OF COLLAGEN IMAGING | EPIX PHARMACEUTICALS, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20070293656-A1 | COLLAGEN BINDING PEPTIDES | EPIX PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913752-B2 | Bivalent bromodomain inhibitors and uses thereof | BRD4, BRD2, BET1 | KDM4E 539/4885CYP1A2 2291/4885CYP2D6 2286/4885 |
| US-20100221261-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC3 | KDM4E 4603/4885CYP1A2 4826/4885CYP2D6 4776/4885 |
| US-20220017432-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | PTGES3, PTGES, HPGDS | KDM4E 4760/4885CYP1A2 708/4885CYP2D6 345/4885 |
| US-20200172553-A9 | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BET1, BRD2 | KDM4E 607/4885CYP1A2 2608/4885CYP2D6 2621/4885 |
| US-20080058636-A1 | METHODS OF MYOCARDIAL IMAGING | FABP3, TNNI3, TNNT2 | KDM4E 4464/4885CYP1A2 4725/4885CYP2D6 4400/4885 |
| US-20080044360-A1 | METHODS OF COLLAGEN IMAGING | COL14A1, COL2A1, COL1A1 | KDM4E 4372/4885CYP1A2 4822/4885CYP2D6 4837/4885 |
| US-20080069812-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents | BIRC5, XIAP, BIRC2 | KDM4E 4355/4885CYP1A2 4758/4885CYP2D6 4622/4885 |
| US-20190169084-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | PTGES3, PTGES, HPGDS | KDM4E 4760/4885CYP1A2 708/4885CYP2D6 345/4885 |
| US-20070293656-A1 | COLLAGEN BINDING PEPTIDES | COL14A1, COL2A1, COL1A1 | KDM4E 4176/4885CYP1A2 4843/4885CYP2D6 4813/4885 |
| US-20080207525-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; bioavailability; coupling; chemical intermediates | BIRC5, XIAP, BAX | KDM4E 4425/4885CYP1A2 4166/4885CYP2D6 3927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.